EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, RLAY: Relay Therapeutics Inc

13 Feb 26 15:59
LAST:

8.930

CHANGE:
 0.12		OPEN:
8.880		HIGH:
9.540		ASK:
0.000		VOLUME:
1.46M
CHG(%):
1.36		PREV:
8.810		LOW:
8.700		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Feb 268.8509.5408.8508.9302.05M
12 Feb 269.1409.3208.3508.8102.22M
11 Feb 268.9409.1608.3609.1502.1M
10 Feb 268.6809.2458.6308.9901.88M
09 Feb 268.9209.1908.5208.6502.76M
06 Feb 268.3809.0108.3308.9203.46M
05 Feb 268.4108.7408.0758.1502.62M
04 Feb 268.7308.9908.2108.4902.67M
03 Feb 268.3908.8908.3008.6705.96M
02 Feb 267.6508.3807.6008.1501.69M

PROFILE

Name:Relay Therapeutics Inc
About:Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:399 Binney Street, Cambridge, MA, United States, 02142
Website:https://www.relaytx.com
CUSIP:75943R102
CIK:0001812364
ISIN:US75943R1023
FIGI:BBG00DSS08K9

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-2.94 
Forward P/E:-5.09 
PEG Ratio:0.07 
Price to Sales:144.24 
Price to Book:2.32 
Operating Margin:-110.11 
Return on Assets:-0.28 
Return on Equity:-0.46 
EPS Ratio:-1.72 
Revenue:8.36M 
Shares:173.32M 
Market Cap:1.548B 

TECHNICAL INDICATORS

MA5:8.910.3%
MA10:8.692.7%
MA20:8.179.3%
MA50:8.129.9%
MA100:7.2922.5%
MA200:5.3866.1%
STO9:56.12
STO14:67.72
RSI14:62.41 
WPR14:-14.67 
MTM14:0.43
ROC14:0.05 
ATR:0.75 
Week High:9.546.8%
Week Low:8.337.2%
Month High:9.546.8%
Month Low:7.0166.1%
Year High:9.546.8%
Year Low:1.77404.5%
Volatility:11.99